Dose-dependent Pharmacological Response to Rituximab in the Treatment of Antineutrophil Cytoplasmic Antibody-associated Vasculitis | Zendy

Jason Springer | Zendy; Ryan S. Funk | Zendy

Open Access

Dose-dependent Pharmacological Response to Rituximab in the Treatment of Antineutrophil Cytoplasmic Antibody-associated Vasculitis

Author(s) -

Jason Springer,

Ryan S. Funk

Publication year - 2021

Publication title -

the journal of rheumatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.577

H-Index - 178

eISSN - 1499-2752

pISSN - 0315-162X

DOI - 10.3899/jrheum.210361

Subject(s) - dosing , medicine , rituximab , regimen , trough concentration , gastroenterology , trough level , granulomatosis with polyangiitis , urology , pharmacology , vasculitis , transplantation , tacrolimus , disease , lymphoma

Rituximab (RTX) is effective in the induction and maintenance of remission in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). However, uncertainty remains regarding the optimal maintenance dosing regimen. This work evaluates the relationship between variability in RTX dosing and pharmacological response in AAV.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research